Abstract. To identify areas endemic for hepatitis C virus (HCV), we attempted to predict the prevalence of antibody to HCV (anti-HCV) in a community by the prevalence of elevated levels of alanine aminotransferase (ALT). The results of health examinations of 2,273 women Ն 40 years old in five townships in central Taiwan were analyzed. The overall prevalence of elevated ALT levels was 11.6%. A township (20.3%) and 10 villages were identified as having a high prevalence (17.9−40.0%) of elevated ALT levels. Five communities with variant rates of elevated ALT levels, which ranged from 8.0% to 27.3%, were selected for correlation with the prevalence of anti-HCV among adults (Ն 40 years old). The prevalence of anti-HCV, which ranged from 10.1% to 72.1%, were obtained by community screenings and/or hospital-based studies. The correlation equation used was the prevalence of anti-HCV (%) ‫ס‬ 3.33 × (prevalence of elevated ALT levels (%) -5.7%) (r 2 ‫ס‬ 0.94, P < 0.01). Using this method, areas endemic for HCV can be identified by determining the community prevalence of elevated ALT levels.
INTRODUCTION
Taiwan is an area endemic for infection with hepatitis B virus (HBV). The carrier rate for hepatitis B virus surface antigen (HBsAg) is approximately 15−20% in the nonvaccinated cohort. 1 The prevalence of antibodies to hepatitis C virus (anti-HCV) among adults in this country is less than 2%. 2, 3 However, some isolated areas endemic for HCV have been reported. 4−11 The major etiology of HCV transmission in these isolated areas was iatrogenic contamination, 8−11 which was also seen in Japanese studies. 12, 13 To prevent and control this problem, identifying all areas endemic for HCV is essential. Because of financial considerations, it is impossible to screen for anti-HCV in the entire population of Taiwan. We attempted to find reasonable surrogates for predicting the prevalence of anti-HCV and identifying areas endemic for HCV.
National Health Insurance has been available in Taiwan since 1995. There have been periodic preventive health examinations of adults covered by National Health Insurance since 1996. All the adults Ն 40 years old are encouraged to have an examination once every three years. A test for alanine aminotransferase (ALT) is included in the examination, but tests for HBsAg and anti-HCV are not.
In a community study in Taiwan, factors significantly associated with elevation of ALT levels were HBsAg, anti-HCV, and obesity.
14 Alcoholism is also another cause of elevated ALT levels. However, obesity-related elevation of ALT levels has low clinical significance. Most patients with chronic HBV infection have elevated ALT levels only in the immune clearance phase. They are usually men less than 40 years old. 15 However, in rural Taiwan, few women habitually drink alcohol. To avoid the confounding effects of HBsAg and alcoholism, we hypothesized that the prevalence of elevated ALT levels among women might be higher in areas endemic for HCV. Thus, the prevalence of elevated ALT levels might be used to predict the prevalence of anti-HCV. The aim of this study was to evaluate the correlation between the prevalence of elevated ALT levels and anti-HCV in tested communities.
MATERIALS AND METHODS

Study areas.
There are 16 counties, five cities, and two metropolitan areas in Taiwan. Our study area was Yunlin County in central Taiwan ( Figure 1A ). Its medical resources are poor. It dose not have a medical center or regional hospital. Five coastal townships were selected for this study: Taishi, Suhu, Kouhu, Sweilin, and Yuenchang ( Figure 1B ). There are 101 villages in these five townships. No previous studies of liver diseases in these areas have been published.
Community-specific prevalence of elevated ALT levels. In 1996, we obtained the results of a preventive health examination of adults covered by National Health Insurance from a regional clinical laboratory. A total of 1,298 men and 2,273 women in the five townships studied were enrolled. Serum ALT levels were determined by an autoanalyzer (TBA-30FR; Toshiba, Tokyo, Japan) and the upper normal limit was set as 40 IU/L. Elevated ALT levels were defined as those greater than 40 IU/L. Township-specific prevalence of elevated ALT levels was obtained in all five townships and villagespecific prevalence of elevated ALT levels was obtained in 57 of 101 villages in these five townships where the number of available cases was 15 or more. Based on the prevalence and case number, the lower limit of the 95% confidence interval (CI) of a village-specific prevalence of elevated ALT levels was selected as the indicator. Villages with a high prevalence and an extraordinarily high prevalence were defined if the indicators were greater than 5% and 10%, respectively.
Prevalence studies of anti-HCV. We obtained the prevalence of anti-HCV in communities by community-based screenings and/or hospital-based studies in some communities with different prevalences of elevated ALT levels. We conducted community-based screenings in two villages. All residents Ն 40 years old were invited by mail and the local broadcast system to participate in our screenings. We also conducted hospital-based studies in two townships. In each study clinic in two townships, all subjects who participated in the preventive health examination of adults in 1997 were re-cruited for our study. The study protocol was reviewing and supported by the National Science Council, Republic of China. All of the study subjects were tested voluntarily with consent. For comparison, one village was studied by both community-based and hospital-based methods.
The venous blood was sampled by a vacuum syringe, was refrigerated in 4°C, and was sent for analysis within four hours. Screening for HBsAg and anti-HCV was done using an automatic enzyme immunoassay (AxSYM; Abbott Laboratories, Abbott Park, IL). A third-generation test for anti-HCV was also used.
Correlation between prevalence of elevated ALT levels and prevalence of HBsAg or anti-HCV. Township-specific or village-specific prevalence of elevated ALT levels obtained from the retrospective collection in 1996 was used to test a correlation with the prevalence of anti-HCV obtained from prospective hospital-based and community-based studies conducted in 1997. The data were analyzed by linear regression and correlation.
Correlation between the prevalence of elevated ALT levels and prevalence of HBsAg or anti-HCV from the data of other community studies in Taiwan. To test the consistency of our results, we enrolled the data from our previous community studies for the same analysis retrospectively. A total of 24 communities in central and southern Taiwan were enrolled, including the five coastal communities in this study, 15 villages in the township of Tzukuan in Kaohsiung County, which is endemic for HCV (residents Ն 45 years old) 5 two townships on the Penghu Islands (subjects 30−64 years old), 16, 17 one community in the blackfoot disease area in Chiayi County (subjects Ն 30 years old) 14 and one community in Tainan County endemic for HBV and HCV (subjects Ն 20 years old). 6 Because the data were obtained from different laboratories and institutes and were completed in different time periods, age distributions of study subjects and the methods for detecting HBsAg, anti-HCV, and ALT were not consistent. The prevalence of anti-HCV ranged from 2.3% to 79.5%, while that of HBsAg ranged from 8.1% to 30.6%. The prevalence of elevated ALT levels among men, women, or both was used to test for a correlation with HBsAg and anti-HCV.
RESULTS
Township-specific and village-specific rates of elevated ALT levels. As shown in Table 1 , the prevalence of elevated ALT levels among men and women were 14.9% and 11.6%, respectively. Taishi township had the highest rates among both men (28.3%) and women (20.3%).
Among the 57 villages studied, six villages had a high prevalence of elevated ALT levels (> 17%) and four other villages had an extraordinarily high prevalence (> 27%). Half (5 of 10) of these villages with high (33%, 2 of 6) or extraordinarily high (75%, 3 of 4) prevalence rates were located in Taishi township, were only eight of the 14 villages had enough cases to be analyzed. (Table 2) Community-based screenings in Wukwai and Haipu. Wukwai was the only village, other than Taishi township, with an extraordinarily high prevalence of elevated ALT levels. Its prevalence rate was 27.3%. Based on official data, approximately 800 individuals Ն 40 years old lived in this village. However, only about half of them lived there permanently. A total of 179 residents (70 men and 109 women) responded to our screening. The prevalence of HBsAg and anti-HCV were 14.0% and 72.1%, respectively.
Haipu had a prevalence of elevated AST levels of 19.3%. It was one of four villages, other than Taishi township, with a high prevalence. A total of 94 residents (47 men and 47 women) were examined. The prevalence of HBsAg and anti-HCV were 17.0% and 38.3%, respectively (Table 3) .
Among the 273 subjects screened in these two communities, 87 (31.9%) had elevated ALT levels. The prevalence of elevated ALT levels was 5% (4 of 80) in those HBsAg-, anti- Hospital-based studies in Taihsi and Sweilin townships. In 1997, we screened 207 adult residents (96 men and 111 women) in Taishi township. The prevalence of HBsAg and anti-HCV were 17.9% and 55.1%, respectively (Table 3) . There was no sex difference in the prevalence of HBsAg or anti-HCV. The influence of sample size on the prevalence of anti-HCV in first 150 cases is shown in Figure 2 . When the number of cases was greater than 15, the prevalence was always within the 95% CI (48.3−61.9%) of the final results.
The sample size (n ‫ס‬ 936) in Sweilin township was large enough to determine the prevalence of elevated ALT levels in all of its 24 villages. If villages shared the same living environment, we grouped them as a community. The 24 villages were grouped as 18 communities. The prevalence was 15−20% in four communities, 10−15% in four, 5−10% in four, and less than 5% in six. We selected three communities with various prevalences of elevated ALT levels to study the prevalence of anti-HCV. In the study clinic, we screened 175 subjects from three study communities: Haipu, Niaosung, and Sweilin. The prevalence of anti-HCV was higher in the community with higher prevalence of elevated ALT levels (Table 3) .
In Haipu village, 23 subjects tested showed an anti-HCV prevalence of 43.5% in the hospital-based study. However, these results were not different from that of the community study (38.5%, 95% CI ‫ס‬ 28.5−48.5%).
Correlation between prevalence of elevated ALT levels and prevalence of HBsAg or anti-HCV. The prevalence rates of elevated ALT levels, HBsAg, and anti-HCV in five study communities are shown in Table 3 . The prevalence rates of HBsAg were constant (11.1−17.9%), while those of anti-HCV ranged from 10.1% to 72.1% and those of elevated ALT levels ranged from 8.0% to 27.3%. The prevalence of elevated ALT levels showed no correlation with the prevalence of HBsAg, but did show a correlation with that of anti-HCV. Correlation between of prevalence of elevated ALT levels and anti-HCV from the data of other community studies in Taiwan. The prevalence of elevated ALT levels did not show a significant correlation with the prevalence of HBsAg in men, women, or both sexes, but it did show a significant correlation with the prevalence of anti-HCV in men, women, and both sexes. This correlation was higher in both sexes (r 2 ‫ס‬ 0.78) than in women (r 2 ‫ס‬ 0.64) or men (r 2 ‫ס‬ 0.49) in predicting the prevalence of anti-HCV (n ‫ס‬ 24). The equation used was 3.16 × ALT (%) -13.6% (r 2 ‫ס‬ 0.78, P < 0.01, n ‫ס‬ 24). It can also be written as anti-HCV (%) ‫ס‬ 3.16 × (ALT (%) -4.3%).
DISCUSSION
In Taiwan, the major etiologic agent of most cases of liver cirrhosis and hepatocellular carcinoma (HCC) is HBV. 18−21 Since the HBV vaccine was developed and promoted, the frequency of this virus and its related sequelae have been decreasing in children. 22−24 However, the importance of HCV is gradually increasing. This virus was first detected in 1989. 25 Although blood transfusion and organ transplantation have not become increased risk factors for transmission of HCV since screening for anti-HCV began, 26, 27 community-acquired hepatitis C has become an important public health problem. In most countries, the prevalence of anti-HCV is less than 5%; in some areas, it is less than 2%. 28 Only a few countries, such as Egypt, have a high nationwide prevalence of anti-HCV. 29 However, there are endemic areas for HCV in coun- tries with a low overall prevalence, such as Taiwan 4−11 and Japan. 12, 13 In addition, some communities endemic for hepatitis C show significant mortality due to HCC. 4 The major factor involved in transmission of HCV might be iatrogenic. 8−13 Thus, identifying areas endemic for this virus is essential for disease control and prevention.
In an attempt to evaluate cost benefits, we analyzed existing data to provide a useful method for identifying all areas endemic for this virus in Taiwan. In our previous study, we analyzed the township-specific mortality due to liver cancer. 4 Hepatocellular carcinoma due to HBV is predominant in men. 30, 31 We attempted to find townships with high mortality rates in both sexes and study the prevalence of anti-HCV. Taishi in this study and Tzukuan in a previous study 4 met this requirement. Among 331 villages in Taiwan, Taishi ranks 13th for men and 14th for women in liver cancer mortality. However, there were limitations in identifying areas endemic for HCV by mortality analysis. Hepatocellular carcinoma develops approximately 30 years after infection with HCV. 32 A high mortality due to HCC is seen only in townships with a long-term prevalence of HCV. We detected an area endemic for HCV with a low frequency of HCC. Hepatitis C is believed to be a newly introduced disease in Paisha Township. 4 Cancer mortality registration is only done at the township level in Taiwan. Thus, we could not identify areas endemic for HCV smaller than a township using official mortality data.
Since mortality is based on death certification, the accuracy of diagnosis of HCC is also a problem.
We also attempted to analyze the geographic differences in viral etiology among HCC patients in hospitals. 30, 33, 34 The time lag between infection with HCV and development of HCC is slightly shorter than that seen in mortality analysis. It is easy to get a confirmed diagnosis of HCC and test results for HBsAg and anti-HCV from hospitals. We did identify areas with a high proportion of HCV-related HCC. There are approximately 6,000 new cases of HCC every year in Taiwan. With the support of the government, a multicenter study is attempting to obtain a sufficient number of cases to identify endemic areas in townships or smaller areas.
According a community study, the presence of HBsAg and anti-HCV, male sex, higher triglyceride levels, and an increase in body mass index were factors related to elevation of ALT levels.
14 Although alcohol, drugs and other rare causes also result in elevation of ALT levels, their significance cannot be identified by multivariate analysis in a community population. Instead of individuals, the subjects were communities in this study. We analyzed data in women to minimize confounding of HBV infection and alcoholism. Our hypothesis is that areas with a higher prevalence of elevated ALT levels among women might endemic for HCV. Nationwide ALT data from preventive health examinations were available. It is less expensive to predict HCV infection by analyzing existing data. Chronicity of HCV infection has been shown to be greater than 85%. 32 This could result in a high prevalence in elevation of ALT levels in communities endemic for HCV.
Our results showed that the equation of linear regression was prevalence of anti-HCV (%) ‫ס‬ 3.3 × (ALT -5.7%). This equation can be explained by documented clinical data. Approximately 5.7% of the elevation in ALT levels results from causes other than HCV infection, and 30% of the patients with positive anti-HCV test results also have elevated ALT levels. 32 The prevalence of elevated ALT levels could be explained by prevalence of anti-HCV because only 5.7% of the elevated ALT levels was induced by causes other than HCV. To test our equation, the data from 24 study communities were analyzed. The first finding of the analysis was a decreased r 2 value. This might result from decreasing homogeneity in the community itself, from the study design (different age groups), and/or from laboratory tests (especially cut-off values for normal ALT values). The results also showed that prevalence of elevated ALT levels in both sexes was the best variable in predicting or estimating the prevalence of anti-HCV. This might be due to weak confounding of HBsAg and alcoholism in these communities. It is reasonable to suggest that the prevalence of anti-HCV in adults can be estimated from the prevalence of elevated ALT levels. A strong correlation between the prevalence of elevated ALT levels and HCV was observed. If the equation is used with data from other areas or countries, it should be re-evaluated and modified according to social background, since there might be different prevalences of HBsAg, alcoholism, obesity, or exposure to other factors. Only 57 of 101 villages with 15 available cases were analyzed in this study. Some endemic areas could have been excluded because of small sample size. The 95% CI was related to both prevalence and sample size. Since sample size and the 95% CI were considered in this study, we could detect areas of high prevalence with increased specificity, but not with increased sensitivity. Thus, some endemic areas with a small study sample could not be identified in this study. A representative sample is also an important issue in a community study. Health examinations not only focus on liver disease, but also on other diseases of adults. Therefore, a less disease-specific selection bias would be generated. Our survey included approximately one-third of the clinics in the study areas. The representative might be acceptable.
According to our hypothesis, areas with a high prevalence of elevated ALT levels should have a high prevalence of infection with HCV. To confirm this, prevalence studies for anti-HCV should be performed. In this study, anti-HCV was used as the marker for estimating HCV infection. Only one of 273 cases screened in the community-based study was anti-HCV-negative but HCV RNA-positive. This can result in a slight underestimation in the prevalence of infection with HCV. In addition, seroreversion of anti-HCV in recovered cases has been observed in other areas endemic for HCV. 35, 36 This might be another cause of underestimation of the prevalence. However, the probabilities of these two situations are too small to influence the prevalence of HCV infection estimated by anti-HCV.
Although community-based studies have good representation, they are also time-consuming and expensive. It is difficult to screen all communities with a high prevalence of elevated ALT levels. We conducted a hospital-based study to determine the prevalence of anti-HCV by screening all participants in a preventive health examination in some local clinics. In one of our study communities (Haipu), the prevalence of anti-HCV in the hospital-based study (43.5%, 10 of 23) was compatible with that in community-based screening (38.3%, 36 of 94). We analyzed the influence of sample size (up to 150 cases) on the prevalence of anti-HCV in the hospital-based study (Figure 2 ). The sample size increased gradually. The prevalence initially fluctuated, but became stationary after the sample size was large enough. When the number of cases was approximately 15, the prevalence was within the 95% CI of our final results. This result might support the theory that a small sample size might be sufficient to estimate prevalence of anti-HCV in hospital-based studies.
In conclusion, we have identified a method for estimating the prevalence of anti-HCV and identifying areas endemic for HCV. A correlation between the prevalence of elevated ALT levels and HCV was demonstrated using nationwide data on ALT levels in the adult population in Taiwan. We also showed that the small sample size in the hospital study might be sufficient to estimate the prevalence of anti-HCV, and that areas endemic for HCV might be of different sizes (townships, villages, or communities). Thus, this method may help resolve public health concerns related to viral hepatitis.
